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ABSTRACT
Background. Perioperative intraperitoneal chemotherapy
is used as an adjunct to cytoreductive surgery (CS) for
peritoneal carcinomatosis (PC) in order to prolong survival.
Worldwide, hyperthermic intraperitoneal chemotherapy
(HIPEC), early postoperative intraperitoneal chemotherapy
(EPIC), and combinations of the two are used. It remains
unclear which regimen is most beneficial.
Methods. The rat colon carcinoma cell line CC-531 was
injected into the peritoneal cavity of 80 WAG/Rij rats to
induce PC. Animals were randomized into four treatment
groups (n = 20): CS only, CS followed by HIPEC (mito-
mycin 35 mg/m2 at 41.5C), CS followed by EPIC during
5 days (i.p. injection of mitomycin on day 1 and 5-fluo-
rouracil on days 2–5), and CS followed by HIPEC plus
EPIC. Primary outcome was survival.
Results. In rats treated with CS only, median survival was
53 days (95% confidence interval (CI) 49–57 days). In rats
treated with CS followed by HIPEC, survival was signifi-
cantly (P = 0.001) increased (median survival 94 days,
95% CI 51–137 days). In the group treated with EPIC after
CS, 12 out of 20 rats were still alive at the end of the
experiment (P \ 0.001 as compared with CS only). In the
group receiving both treatments, 11 rats died of toxicity, and
therefore this group was not included in the survival analysis.
Conclusions. Both EPIC and HIPEC were effective in
prolonging survival. The beneficial effect of EPIC on sur-
vival seemed to be more pronounced than that of HIPEC.
Further research is indicated to evaluate and compare the
possible benefits and adverse effects associated with both
treatments.
The combination of cytoreductive surgery (CS) and
perioperative intraperitoneal chemotherapy is the only
available curative option for patients with peritoneal carci-
nomatosis (PC) from colorectal cancer. By now, it has been
widely accepted as the treatment of choice for patients with
limited peritoneal carcinomatosis who are fit for major sur-
gery. The aim of this treatment is to radically remove all
visible tumor deposits from the peritoneal cavity, and to
eradicate residual microscopic disease by adjuvant applica-
tion of intraperitoneal chemotherapy. Promising results have
been shown by several centers, achieving median survival
which compares favorably with the outcomes of patients
treated with palliative care, in whom life expectancy is
usually limited to approximately 6 months.1–5
The adjuvant intraperitoneal chemotherapy can be
applied directly after cytoreduction under hyperthermic
conditions (hyperthermic intraperitoneal chemotherapy,
HIPEC) as a part of the surgical procedure, or can be
started on the first postoperative day and continued for
several (usually five) days (early postoperative intraperi-
toneal chemotherapy, EPIC). Both techniques are currently
offered to patients with colorectal PC, either as separate
treatments or in combination, depending on the preference
of the center and surgeon.
The choice for HIPEC and/or EPIC has major conse-
quences for the scheduling of procedures and the capacity
of the treatment center. This becomes relevant as growing
awareness among physicians about the availability of
treatment possibilities for PC results in increasing numbers
of patients being referred to specialized centers.
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No randomized controlled trials have been published
comparing the survival outcomes after EPIC and HIPEC.
Furthermore, it is unclear whether the combination of
HIPEC and EPIC results in superior outcomes.
In a recent experimental study, it was shown that adju-
vant application of HIPEC after CS can prolong survival as
compared with CS only.6 A second study demonstrated
beneficial results for both adjuvant normothermic and
hyperthermic intraoperative perfusion.7
In the present study, the effectiveness of HIPEC and
EPIC as adjuvant treatment after CS was evaluated in a
well-established model for PC in rat. In addition, the
combination of the two treatments was investigated. Sur-
vival is the primary outcome parameter.
METHODS
Experimental Design
PC was induced in all animals 7 days before the surgical
procedures. Rats were assigned to one of four treatment
groups (n = 20 each) by randomization. Treatment per
group was as follows: group 1 (CS), exploration followed
by cytoreductive surgery only; group 2 (HIPEC), cytore-
ductive surgery plus hyperthermic intraperitoneal perfusion
with mitomycin at 41C for 90 min; group 3 (EPIC),
cytoreductive surgery followed by early postoperative
chemotherapy from the first day postoperatively using
mitomycin on the first day and 5-fluorouracil (5-FU) on
days 2–5; group 4 (HIPEC?EPIC), cytoreductive surgery
followed immediately by HIPEC and EPIC. Primary out-
come parameter was survival.
Animals
Eighty male WAG/Rij rats (10–12 weeks old, mean
weight 267 ± 8.2 g) were obtained from Harlan, Horst, The
Netherlands. The animals were housed in filter-topped cages
(three rats per cage) under clean, nonsterile standardized
conditions (temperature 20–24C, relative humidity
50–60%, 12 h light/12 h dark) with free access to water
and chow (Ssniff; Bio services, Uden, The Netherlands).
Accustomization to laboratory conditions was allowed for at
least 1 week before the start of the experiment. All experi-
ments were approved by the Animal Welfare Committee of
Radboud University Nijmegen Medical Centre and carried
out in accordance with the Dutch Animal Welfare Act 1997.
Induction of Peritoneal Carcinomatosis
Two milliliters of a suspension containing a concentra-
tion of 106 cells/mL of the syngeneic rat colon carcinoma
cell line CC-531 was injected intraperitoneally in all ani-
mals as described elsewhere to induce peritoneal
carcinomatosis.8
Surgery
One week after tumor cell inoculation, CS was per-
formed in all animals under general anesthesia using
isoflurane 3%, O2 and N2O 1:1. Carprofen (5 mg/kg/day)
was given for analgesia 30 min prior to surgery and once
daily until the third postoperative day. To limit body heat
loss, all rats were placed on a warmed mattress during the
procedure.
The abdominal cavity was opened and exposed by
complete midline laparotomy, and all abdominal regions
were systematically inspected for tumor deposits. The
peritoneal cancer index (PCI) representing the extent of
peritoneal carcinomatosis was recorded as the sum of all
scores, as described previously.6,7
All animals underwent CS with standard resection of the
greater omentum aiming at radical removal of all macro-
scopic tumor deposits. CS may include resection of fat
pads, spleen, parts of the mesentery, and peritonectomy.
No bowel resections are performed in this experimental
model, and no anastomoses are made. Due to the small size
of the animals, some tumor localizations are impossible to
reach while performing surgical resection. Small lesions
that are not suitable for resection due to their localization
are cauterized using an electrocoagulation device. These
cauterized deposits are considered as completely treated, as
no visible vital tumor tissue is left behind. After the best
achievable cytoreduction, the amount of residual tumor
was scored in accordance to current clinical practice using
the R1–R2a–R2b classification: R1, no macroscopic dis-
ease left; R2a, tumor smaller than 2.5 mm left behind; R2b,
residual tumor mass larger than 2.5 mm.
In both the CS and EPIC groups the abdomen was
closed. In the HIPEC and HIPEC?EPIC groups, surgery
was followed immediately by heated intraperitoneal
perfusion.
HIPEC
Perfusion of the abdomen was performed with a closed
technique as described before.6,9 The peritoneal perfusate
consisting of 250 mL NaCl (0.9%) was warmed to 41.5C
and infused into the abdomen at 10 mL/min during 90 min.
Mitomycin-C (Nycomed Christiaens BV, Breda, The
Netherlands) was dissolved in saline and added to the
perfusate in three separate gifts at 30 min intervals, each
containing 50%, 25%, and 25% of the total dose of 35 mg/m2
mitomycin. During the perfusion, gentle massage of the
abdomen was applied to equalize fluid distribution in the
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peritoneal cavity. Subsequently the abdominal wall was
closed in two layers using continuous Vicryl 3/0 sutures.
All animals received subcutaneous injection of 10 mL
0.9% NaCl for rehydration.
EPIC
Intraperitoneal chemotherapy was administered with a
single daily intraperitoneal injection (0.75 ml). On the first
day following surgery, mitomycin was given at a dose of
10 mg/m2 (1.36 mg/kg). From the second postoperative
day onwards a dose of 15 mg/kg 5-fluorouracil was given
to each rat intraperitoneally. The last gift of 5-fluorouracil
was administered on day 5.
Follow-up and Autopsy
During the first week after surgery, general condition
and body weight of the animals were assessed daily. After
the first week, general condition and body weight were
recorded at least twice weekly and more often if symptoms
of discomfort were present. Survival was the primary
endpoint of this study.
Humane endpoints were chosen to minimize or termi-
nate pain or distress to the experimental animals via
euthanasia rather than waiting for death as the endpoint.
The following humane endpoints were used:
The animal refuses intake of food and fluids, shows
rapid weight loss, severe circulation or breathing problems,
strongly abnormal behavior, severe clinical symptoms or
disabling consequences of ascites or tumor growth, or the
expectation is raised that the animal will die shortly.
Whether these endpoints were reached was determined
by an experienced biotechnician blinded to the animals’
assigned treatment groups.
When the humane endpoint was reached, rats were
killed by O2/CO2 asphyxiation and autopsied.
At autopsy, the weight of ascites (if present) was mea-
sured and the extent of intraperitoneal tumor load was
recorded using the same PCI scoring system as described
above. The experiment was terminated at 168 days post-
operatively (24 weeks). The rats that were still alive at that
time were euthanized and autopsied.
In case no macroscopic tumor deposits were found at
autopsy, the greater omentum and diaphragm were
removed and microscopically examined for presence of
tumor growth. Hematoxylin and eosin (H&E) staining and
murine MG1 antibody in combination with a horse anti-
mouse immunoglobulin G (IgG) antibody, horseradish
peroxidase (HRP) conjugated (Vector Laboratories Inc.,
Burlingame, CA, USA) were used for microscopic evalu-
ation of the samples.
Statistical Analysis
Statistical analysis was performed using Graphpad
Prism (version 4.0, 2003; Graphpad Software Inc., San
Diego, CA) and SPSS (version 17.0, 2007, Chicago, IL)
software. One-way analysis of variance (ANOVA) testing
was used for comparison of continuous values. The com-
parison of dichotomous values was performed with chi-
square or Fisher’s exact test.
Kaplan–Meier curves were used for survival analysis
and compared by means of the log-rank test. To correct for




All animals underwent cytoreductive surgery. No dif-
ferences were observed between groups regarding
preoperative clinical condition or mean body weight.
Macroscopic peritoneal carcinomatosis was present in
all animals. An example of macroscopic tumor growth is
shown in Fig. 1a. The greater omentum, perisplenic area,
liver hilum, mesentery, and intra-abdominal site of tumor
inoculation were the most commonly affected sites of
tumor growth. Detailed PCI is given in Table 1. Median
PCI before cytoreduction was similar in all treatment
groups (P = 0.429).
No difference in results of CS in terms of residual dis-
ease were observed between the treatment groups
(P = 0.343). Mean time of the CS procedures was 26
(standard deviation, SD 6) min without differences
between groups (P = 0.221).
Perfusion Characteristics
Mean intra-abdominal temperature at the inflow site was
41.5C (SD 0.44C). Mean rectal and intra-abdominal
temperatures during perfusion are shown in Fig. 2. The
perfusion characteristics were similar in both HIPEC and
HIPEC?EPIC groups.
Early Follow-up
Figure 3 shows the course of body weight during the
first 14 days after surgery in the four groups.
Rats in the CS group generally gained weight from
postoperative day 2 onwards. In the HIPEC group, rats
started gaining weight after day 6. Rats receiving EPIC
(with or without HIPEC) reached their minimum weight on
day 7. In both groups receiving EPIC, the maximum weight
HIPEC versus EPIC for Peritoneal Carcinomatosis S477
FIG. 1 Examples of macroscopic tumor deposits found during initial exploration of the abdomen on the kidney (a) and during autopsy at liver
(b), omentum (c), and mesentery (d)
TABLE 1 Tumor score before
cytoreduction and results of
cytoreductive surgery





PCI peritoneal cancer index
Group CS EPIC HIPEC HIPEC?EPIC
Preoperative weight (g), mean (SD) 267 (7) 265 (9) 268 (9) 267 (8)
Tumor score per site, median (range)
Subcutaneous 1 (0–2) 1 (0–1) 1 (0–1) 1 (0–2)
Inoculation site intra-abdominal 1 (0–3) 1 (0–3) 1 (0–2) 1 (0–3)
Greater omentum 1 (1–1) 1 (0–2) 1 (1–3) 1 (1–1)
Liver hilum 1 (0–1) 1 (0–1) 1 (1–3) 1 (1–2)
Liver surface 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0)
Spleen 1 (0–1) 1 (0–1) 1 (1–2) 1 (0–2)
Mesentery 1 (1–3) 1 (0–3) 1 (1–2) 1 (0–3)
Fat pad left 0 (0–1) 0 (0–1) 0.5 (0–1) 0 (0–1)
Fat pad right 0 (0–2) 0.5 (0–2) 1 (0–2) 0 (0–2)
Diaphragm 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–2)
Parietal peritoneum 0 (0–3) 0 (0–2) 0 (0–3) 0 (0–3)
PCI, mean (SD) 8.0 (2.9) 7.3 (2.0) 8.3 (1.8) 7.4 (2.0)
Splenectomy (n)
Yes 1 1 3 3
No 19 19 17 17
Completeness of resection (n)
R1 16 19 18 18
R2a 2 1 2 2
R2b 2 0 0 0
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loss was higher than in the CS group (CS versus HIPEC,
P = 0.056; CS versus EPIC and CS versus HIPEC?EPIC,
P \ 0.001).
Eight deaths occurred in the early postoperative course
(two HIPEC, three HIPEC?EPIC, two CS, and one EPIC)
unrelated to tumor growth. In the CS group, one rat died of
postoperative ileus after 4 days. The other rat died of
unknown reasons after 3 days. In the EPIC group, one rat
died after 12 days because of obstruction caused by her-
niation of the ileum through a mesentery defect. In the
HIPEC group, two unexpected deaths occurred, one after
7 days because of an abscess in the upper abdomen, and
one caused by respiratory failure immediately following
the surgical procedure, possibly related to excessive blood
loss during CS. In the HIPEC?EPIC group, deaths were
caused by bowel perforation and necrosis after 2 days and
abscess formation in the liver hilum resulting in obstruction
and progressive icterus after 15 days. One rat was found
dead after 8 days, and the cause of death remained unclear.
In the HIPEC?EPIC group, a late unexpected death
occurred after 86 days. At autopsy, herniation of the small
bowel was found. All rates mentioned above were marked
as censored in the survival analysis.
Rats in the HIPEC?EPIC group initially recovered from
the procedures and gained weight from day 8 onwards.
However, after several weeks rats started to lose weight
again to die eventually from excessive weight loss. This
course was observed in 11 rats. At autopsy, no tumor was
found in these animals, nor any evidence for another cause
of death. Only four rats died from the consequences of
tumor growth. At the end of the experiment, two rats were
alive. Given the large number of rats dying from non-
tumor-related causes in this group, the effect of treatment
on survival could not be evaluated, and therefore it was
decided not to include this group in the survival analysis.
Survival and Post Mortem Findings
Figure 4 shows the Kaplan–Meier survival analysis
for each group. Median survival in the group treated with
CS only was 53 days (95% confidence interval (CI)
49–57 days). In the group of rats receiving HIPEC perfu-
sion, median survival of 94 days (95% CI 51–137 days)
was observed. In the EPIC group, 12 animals were still
alive when the experiment was ended and therefore median
survival could not be recorded, but it was at least 168 days.
Survival outcomes were compared between groups,
correcting for completeness of resection and preoperative
PCI. Survival outcomes in both adjuvant treatment groups
were significantly better as compared with the CS group:
FIG. 3 Postoperative course of mean relative body weight
FIG. 4 Kaplan–Meier analysis of overall survival, per group
FIG. 2 Rectal and intra-abdominal temperatures during perfusion
procedures. Data represent mean ± SD (n = 40) of temperature
measurements during HIPEC in all animals from both HIPEC and
HIPEC?EPIC groups
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HIPEC versus CS (P = 0.001, hazard ratio for dying 0.24,
95% CI 0.10–0.55) and EPIC versus CS (P \ 0.001, haz-
ard ratio 0.10, 95% CI 0.04–0.28).
Nineteen rats were still alive at the time of maximum
follow-up of 168 days. At autopsy 11 of these rats
appeared to be macroscopically free of tumor and ascites
(1/2 CS, 3/5 HIPEC, 7/12 EPIC). In all of these rats, the
remaining omentum and diaphragm were removed and
stained for histological examination. No microscopic evi-
dence of disease was found.
Rats from the CS group that reached their humane
endpoint during follow-up showed a higher mean PCI at
autopsy than rats treated with HIPEC (P = 0. 004) or EPIC
(P \ 0.001). The differences in the amount of ascites
present at autopsy remained statistically insignificant for
both adjuvant treatment groups as compared with the CS
group. Post mortem findings are summarized in Table 2.
On multivariate analysis, the influence of PCI and com-
pleteness of resection on survival outcomes did not reach
significance (P = 0.065 and P = 0.164, respectively).
DISCUSSION
In this experimental study, both EPIC and HIPEC were
effective in prolonging survival when applied as adjuvant
treatment after CS. Always keeping in mind the difference
between rodents and humans, this finding may have
important implications for clinical practice.
The scheduling of EPIC treatment has several logistical
advantages when compared with HIPEC. For the perfor-
mance of a HIPEC procedure, careful and punctual
scheduling of the surgical procedure is essential. Intraop-
erative administration of heated chemotherapy requires the
availability of the chemotherapeutic agent in the operating
room, safety precautions for both the patient and the per-
sonnel involved in the procedures, specialized technical
equipment which is adequately cleaned and/or sterilized,
and the presence of an experienced perfusionist. In con-
trast, for administration of EPIC, insertion of a peritoneal
port at the end of a surgical procedure is an easier and less
time-consuming procedure. The intraperitoneal treatment
itself can be performed at an intensive care unit or even
hospital ward. Furthermore, EPIC can be offered ad hoc to
patients in whom peritoneal carcinomatosis is discovered
incidentally during laparotomy, which is a common way of
diagnosing this disease. However, performance of EPIC
has been associated with an increased risk of complications
after extensive abdominal surgery in some retrospective
studies.10,11 This theoretically may be a consequence of the
prolonged contact of chemotherapy with newly performed
anastomoses and operated surfaces, thereby delaying
wound healing and recovery. Indeed, experimental studies
have shown that both HIPEC and intraperitoneal injection
of chemotherapy have a negative influence on wound
strength.12,13
Other disadvantages of EPIC may be a less equal dis-
tribution of fluid in the abdomen and patients experiencing
physical discomfort (nausea, impaired mobility) associated
with the intra-abdominal presence of the chemotherapy for
5 days. However, other studies reported no differences in
complications between HIPEC and EPIC.14,15 To date, no
randomized controlled trials have been reported comparing
the two techniques in this respect.
Previously published animal experiments have shown
that the timing of intraperitoneal chemotherapy treatment
after tumor cell application is a relevant factor influencing
the effectiveness of treatment. It has been described that
administration of anticancer agents immediately after
tumor cell inoculation can eliminate all disease, whereas
late administration (later than 3 days after tumor inocula-
tion, when usually macroscopic disease is present) may
slow down tumor growth but cannot be used with curative
intent.16–20 The current study shows, in accordance with
the experimental literature mentioned, that the application
of intraperitoneal chemotherapy 1 day after surgery is
still effective to eliminate microscopic tumor cells after
cytoreductive procedures, without use of hyperthermic
circumstances. Twelve animals from the EPIC group and
five animals from the HIPEC group were alive at the end
of the follow-up period of 24 weeks. Three animals from
the HIPEC and seven from the EPIC group were free of
microscopic tumor.
Due to the experimental design of this study, choices
such as the HIPEC conditions applied had to be made,
which always constitute a certain degree of bias. Although
the flow rate in rats may be lower than in the human sit-
uation, it is thought unlikely that this would explain the
survival outcomes of this study. To our knowledge, the
flow rate is not a commonly reported prognostic factor in
patients treated with HIPEC. In the rats receiving EPIC,
chemotherapy was given as a low-volume intraperitoneal
injection, resulting in no flow or pressure at all.
A direct cytotoxic effect of higher temperatures (excee-
ding 42–43C) on both normal and tumor cells has been
observed under experimental conditions.21,22 In HIPEC
treatment, however, direct cytotoxicity by hyperthermia is
not a primary goal. The hyperthermia applied in this
TABLE 2 Post mortem findings
Group CS EPIC HIPEC P-value
PCI, mean (SD) 27 (4) 14 (10) 19 (6) \0.001
Ascites weight (g), mean (SD) 27 (23) 40 (26) 43 (20) 0.136
CS cytoreductive surgery, EPIC early postoperative intraperitoneal
chemotherapy, HIPEC hyperthermic intraperitoneal chemotherapy,
PCI peritoneal cancer index
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treatment is aimed at a synergetic effect with chemotherapy.
Therefore, in this animal model, lower temperatures are
used, based on the HIPEC technique that was described in
the only completed randomized phase III trial evaluating
the effectiveness of HIPEC using an inflow temperature of
41–42C.1
The necessity of hyperthermia in the treatment of peri-
toneal carcinomatosis has never been proven.
Although mild hyperthermia as applied in HIPEC is
thought to increase blood flow and oxygen content within
tumors, thereby increasing drug concentrations and enhan-
cing the antitumor effect, the presumed beneficial effect on
patient survival has never been investigated in randomized
trials.22,23 In retrospective studies, no difference between
normothermic and hyperthermic administration of mito-
mycin followed by EPIC was found.24 In a recent
experimental study, normothermic and hyperthermic intra-
operative perfusion were both effective in prolonging
overall survival in rats with peritoneal carcinomatosis, and
with both treatments several animals remained free of dis-
ease until the end of the follow-up period.7 In a study by
Zeamari et al., similar results were obtained, although no
cytoreductive surgery was performed.25 Also in the current
study, the performance of EPIC (under normothermic con-
ditions) was shown to be at least equally effective as
the treatment including hyperthermia. Therefore, further
research into the necessity of hyperthermia should be per-
formed to investigate if indeed simplification of the current
multimodality treatment for peritoneal carcinomatosis is
possible.
In theory, EPIC and HIPEC may be combined to obtain
optimal oncologic outcome. However, a risk of toxicity of
the high dose of chemotherapy should always be taken into
account when considering the combination of treatments.
In the current study most rats treated with HIPEC?EPIC
suffered from severe toxicity as illustrated by the weight
loss during the first two postoperative weeks. In the end
most rats died after several weeks with symptoms sug-
gesting late toxicity. For further evaluation of the
combination of HIPEC and EPIC in experimental studies, it
may be useful to use only 5-FU in the EPIC regimen in
order to decrease toxicity.
In conclusion, both HIPEC and EPIC prolonged survival
when used as adjuvant therapy after cytoreductive surgery
for peritoneal carcinomatosis from colorectal cancer in an
experimental model. Further research is required to eval-
uate and compare the possible beneficial and adverse
effects associated with both treatments in daily clinical
practice. In this way the optimal treatment strategy for
patients suffering from peritoneal carcinomatosis of colo-
rectal origin will be further improved.
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